Immediate Impact
1 from Science/Nature 52 standout
Citing Papers
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2024 Standout
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
Works of Mathias Haenel being referenced
First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)
2020
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
2012
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mathias Haenel | 262 | 87 | 293 | 178 | 35 | 495 | |
| José C. Díaz‐Maqueo | 287 | 96 | 252 | 83 | 32 | 515 | |
| Leanne Berkahn | 147 | 83 | 247 | 123 | 35 | 458 | |
| Michio Sawada | 204 | 61 | 299 | 79 | 37 | 571 | |
| F. B. Hagemeister | 325 | 55 | 296 | 79 | 22 | 553 | |
| Benjamin M. Parsons | 199 | 32 | 250 | 127 | 33 | 435 | |
| E.‐W. Schwarze | 122 | 60 | 278 | 84 | 37 | 463 | |
| M. Crump | 176 | 73 | 184 | 120 | 20 | 453 | |
| Edna L. García | 284 | 38 | 228 | 63 | 29 | 468 | |
| Roberto Freilone | 314 | 89 | 414 | 150 | 44 | 575 | |
| Vittorio Meneghini | 172 | 104 | 314 | 137 | 21 | 503 |
All Works
Loading papers...